Market Research Report
Penicillin Market by Product, Type, Manufacturing Process, Mode of Delivery, and End User and By Geography - Analysis, Size, Share, Trends, & Forecast from 2021-2027
|Penicillin Market by Product, Type, Manufacturing Process, Mode of Delivery, and End User and By Geography - Analysis, Size, Share, Trends, & Forecast from 2021-2027|
Published: October 1, 2020
AnalystView Market Insights
Content info: 237 Pages
Delivery time: 2-3 business days
Penicillin Market by Product (Bulk and Dosage), Type (Aminopenicillin, Antipseudomonal Penicillin, Beta-lactamase Inhibitor, Natural Penicillin, and Penicillinase-resistant Penicillin), Manufacturing Process (Synthetic Process, Natural Process, and Semisynthetic Process), Mode of Delivery (Oral, Intramuscular, and Intravenous), and End User (Hospitals, Clinics, and Research Institutes) and By Geography (EU, NA, APAC, LATAM, and MEA) - Analysis, Size, Share, Trends, & Forecast from 2021-2027.
The global Penicillin market was valued at USD 1.72 billion by 2019, growing with 4.28% CAGR during the forecast period, 2021-2027.
Penicillin (PCN or pen) is a cluster of antibiotics resulting from common molds called Penicillium molds, which comprises penicillin V (use by mouth), penicillin G (intravenous use), benzathine penicillin (intramuscular use), and procaine penicillin. These specialized antibiotics were amongst the principal medications to be active against various microbial contagions produced by streptococci and staphylococci. They are extensively used, though numerous types of microbes have developed resistance on subsequent broad use.
Around 10% of populaces report that they are sensitive to these antibiotics; nevertheless, up to 90% of these people may not be sensitive. Severe allergies merely occur in around 0.03%. These are B-lactam antibiotics, a few of the top successful and influential accomplishments in modern science.
The upsurge in the occurrence of transmissible diseases and an increase in investments for research and development are important elements that impel the Penicillin market growth. Moreover, an increase in generic medications' needs is expected to drive growth. Conversely, patent expiry for the antibiotic manufacturing and rigorous government guidelines to limit the usage of antibiotics and are chief factors that impede growth. Also, an increase in antimicrobial resistance of bacteria and innovative antibiotics with reduced adverse effects obstruct the growth. Conversely, innovative product development and antibiotic usage in different cell cultures as an effective antibacterial agent are predictable to deliver potential lucrative opportunities for market extension.
Also, few supportive government regulations, such as the Generating Antibiotics Incentives Now (GAIN) Act, are likely to accelerate the authorization and approval process. The Act has provisions, which enable the growth of therapies in contradiction of antibiotic-resistant pathogens.
Depending upon Product, the global business is categorized into bulk and dosage. The bulk category occupied the lion's share in 2019 and anticipated to witness the remarkable growth during the analysis period, owing to the lower pricing. According to the UK-based Michael Barber & Associates (MBA), recent bulk product prices are the lowermost ever.
Besides, increasing government support is driving the market growth. For illustration, the Indian government declared the contours of a scheme to increase the production of around 41 bulk drugs - ranging from ingredients to antibiotics for lifesaving tuberculosis and heart drugs like vitamin B1, penicillin-G, diclofenac sodium, and prednisolone.
In terms of type, the worldwide industry is categorized into Aminopenicillin, Antipseudomonal Penicillin, Natural Penicillin, Beta-lactamase Inhibitor, and Penicillinase-resistant Penicillin. Aminopenicillin is likely to grow in the future due to the snowballing pool of patients suffering from bacteriological infections. The great cost of novel drugs are elements expected to foster the market extraordinarily in the next few years. The increasing level of awareness, continued product launches of effective drugs, better treatment facilities, and the existence of favorable government reimbursement policies for high-cost treatments are also expected to drive the global amino penicillin drug market during the prediction period.
Manufacturing Process Takeaway
By manufacturing process, the market is classified into a synthetic process, natural process, and semisynthetic process. The synthetic process held a remarkable share in 2019, and the natural and semisynthetic is projected to witness a notable CAGR during the forecast period. Amoxycillin (i.e. α-amino-p-hydroxy benzylpenicillin) is one of the newly developed semisynthetic penicillin with a comprehensive spectrum of antibacterial activity similar to that of antibiotic ampicillin.
Route of Delivery Takeaway
The worldwide industry is classified into oral, intramuscular, and intravenous based on the mode of delivery. The intravenous route has occupied a remarkable share in 2019 and is projected to grow at a considerable CAGR during the timeframe. The intravenous mode of delivery provides for controlled and persistent plasma profiles and supreme infusion volumes. The fast dilution of intravenous solutions in the bloodstream permits a superior tolerance of the antibiotic with injection site tolerance associated with subcutaneous or intramuscular dosing.
In terms of end-user, the worldwide industry is categorized into hospitals, clinics, research institutes, and others. The hospital segment generated the maximum revenue in 2019 and is foreseen to maintain its global dominance throughout the prediction period, as it is used to treat both upper & lower respiratory tract infections.
Special regulatory provisions by the government and greater efficacy of antibiotics toward various urinary tract infections and lower & upper respiratory contagions are the key factors driving the global market. However, growing antibiotic resistance and the slow registration process of national regulatory authorities are anticipated to affect the growth during the forecast period.
Regionally, the overall industry is divided into North America, Middle East & Africa, Asia Pacific, Latin America, and Europe. North America is considered to be the most attractive market due to the rising incidence of contagious diseases. This dominance is due to the rising number of antibiotic producers in the Asian nations and the existence of the world's prominent generic manufacturers in the region.
Moreover, the rising prevalence of contagious infections such as MRSA infections and Clostridium difficile and mounting patient awareness are some other factors that will foster growth in the APAC market. Latin American countries such as Brazil and Mexico are anticipated to have substantial potential to foster growth due to bacterial infections' high incidences and developing medical care infrastructure.
The rise of the COVID-19 pandemic brought the world together to a standstill. Nevertheless, the market for antibiotics, including Penicillins, has seen a surge across the world. Since the novel coronavirus pandemic began, inadequate data from small studies in different countries have shown tremendous rates of antibiotic prescribing in coronavirus patients and growing use of unnecessary antibiotic, and the pandemic's potential impact on antimicrobial resistance (AMR), according to a news article from the CIDRAP (Center for Infectious Disease Research and Policy) at the University of Minnesota, U.S.
Key Vendor Takeaway
The global Penicillin market players include Pfizer, Merck & Co., Inc., Novartis AG, F. Hoffmann-La Roche Ltd., Astellas Pharma Inc., GlaxoSmithKline plc., Gilead Sciences Inc., Toyama Chemical Co., Ltd, MiddleBrook Pharmaceuticals, Inc., Sanofi Aventis SA, Takeda Pharmaceutical Company Ltd., Eli Lilly, Celgene, Bristol Myers Squibb C, Biogen IDEC, Bayer HealthCare AG, Amgen, Bristol Myers Squibb Co., Abbot among others.
The major players are actively adopting various strategies such as acquisition, geographical expansion, development of new and efficient therapeutics, etc. to maintain their position in the market. Also, the companies are involved in the strategic development of new products, such as in February 2020, Grifol acquired Aradigm. The acquisition would help to strengthen the antibiotic portfolio of Grifol.
The market size and forecast for each segment and sub-segments has been considered as below:
Historical Year - 2016 to 2018
Base Year - 2019
Estimated Year - 2020
Projected Year - 2021 to 2027
Traders, Distributors, and Suppliers
Government and Regional Agencies
SCOPE OF THE REPORT
The scope of this report covers the market by its major segments, which include as follows:
GLOBAL PENICILLIN MARKET KEY PLAYERS
Merck & Co., Inc.
Hoffmann-La Roche Ltd.
Astellas Pharma Inc.
Gilead Sciences Inc.
Toyama Chemical Co., Ltd
MiddleBrook Pharmaceuticals, Inc.
Sanofi Aventis SA
Takeda Pharmaceutical Company Ltd.
Bristol Myers Squibb C
Bayer HealthCare AG
Bristol Myers Squibb Co
GLOBAL PENICILLIN MARKET BY SPECTRUM OF ANTIMICROBIAL ACTIVITY
GLOBAL PENICILLIN MARKET BY FORMULATION
GLOBAL PENICILLIN MARKET BY TYPES
GLOBAL PENICILLIN MARKET BY ROUTE OF ADMINISTRATION
GLOBAL PENICILLIN MARKET BY APPLICATION
Sexually Transmitted Disease
Respiratory Tract Infection
Urinary Tract Infection
Others (Acute Abdomen Infection, Meningitis, and Pelvic infection)
GLOBAL PENICILLIN MARKET BY FORMULATION
GLOBAL PENICILLIN MARKET, BY REGION
Rest of Europe
Rest of APAC
Rest of LATAM
The Middle East and Africa
United Arab Emirates
Rest of MEA
Type segment market share analysis, 2020 & 2027